Alcohol Use Disorder (AUD)
6
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Alliance PharmaceuticalsUK - Wiltshire
2 programs1
1
BrexanolonePhase 21 trial
DexmedetomidinePhase 12 trials
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Alliance PharmaceuticalsDexmedetomidine
Alliance PharmaceuticalsBrexanolone
Tempero BioTMP-301
Alliance PharmaceuticalsDexmedetomidine
Novo NordiskDCR-AUD
Clinical Trials (5)
Total enrollment: 236 patients across 5 trials
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Start: Feb 2003Est. completion: Oct 200740 patients
Phase 4Completed
Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Start: Jul 2025Est. completion: Mar 202740 patients
Phase 2Not Yet Recruiting
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
Start: Nov 2024Est. completion: Nov 2025110 patients
Phase 2Active Not Recruiting
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Start: Jul 2025Est. completion: May 202610 patients
Phase 1Recruiting
Study of DCR-AUD in Healthy Volunteers
Start: Sep 2021Est. completion: Dec 202236 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 236 patients
4 companies competing in this space